Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified

Chinese Journal of Lung Cancer

Volumn 16, Issue 3, 2013, Pages 138-143

  Song, Zhengbo ^a   Yu, Xinmin ^a,b   Cai, Jufen ^a,b   Shao, Lan ^a,b   Lin, Baochai ^a,b   He, Chunxiao ^a,b   Zhang, Beibei ^a,b   Zhang, Yiping ^a,b  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology   (China)

Author keywords

Efficacy; EGFR mutation; Icotinib; Lung neoplasms

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ICOTINIB;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; GENE; GENE MUTATION; HUMAN; MONOTHERAPY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TOXICITY; UNSPECIFIED SIDE EFFECT;

EID: 84922687467     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2013.03.04     Document Type: Article

References (15)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin, 2010, 60(5): 277-300.
2. Gyula O, Andras B, Zoltan B, et al. Basic principles for the prevention, diagnosis and therapy of lung cancer. Magy Onkol, 2012, 56(2): 114-132.
3. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 2002, 346(2): 92-98.
4. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 2005, 353(2): 123-132.
5. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 2005, 366(9496): 1527-1537.
6. Sun Y, Shi Y, Zhang L, et al. A randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN). J Clin Oncol, 2011, 29(suppl): 7522.
7. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol, 2010, 11 (2): 121-128.
8. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 2010, 362(25): 2380-2388.
9. Tan F, Shen X, Wang D, et al. Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer, 2012, 76(2): 177-182.
10. Garassino MC, Martelli O, Bettini A, et al. TAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR. J Clin Oncol, 2012, 30(suppl): 7501.
11. Costa DB, Kobayashi S. Are exon 19 deletions and L858R EGFR mutations in non-small-cell lung cancer clinically different? Br J Cancer, 2007, 96(2): 399.
12. Wu JY, Yu CJ, Yang CH, et al. First-or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer. Am J Respir Crit Care Med, 2008, 15(8): 847-853.
13. Ruppert AM, Beau-Faller M, Neuville A, et al. EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up. Eur Respir J, 2009, 33(2): 436-440.
14. Gounant V, Wislez M, Poulot V, et al. Subsequent brain metastasis responses to epidermal growth factor receptor tyrosine kinase inhibitors in a patient with non-small-cell lung cancer. Lung Cancer, 2007, 58(3): 425-428.
15. Gu A, Shi C, Xiong L, et al. Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer. Chin J Cancer Res, 2013, 25(1): 90-94.